1 |
A'Hern RP (2001). Sample size tables for exact single-stage phase II designs, Statistics in Medicine, 20, 859-866.
DOI
|
2 |
Bryant J and Day R (1995). Incorporating toxicity considerations into the design of two-stage phase ii clinical trials, Biometrics, 51, 1372-1383.
DOI
|
3 |
Cai C, Liu S, and Yuan Y (2014). A Bayesian design for phase II clinical trials with delayed responses based on multiple imputation, Statistics in Medicine, 33, 4017-4028.
DOI
|
4 |
Chen K and Shan M (2007). Optimal and minimax three-stage designs for phase II oncology clinical trials, Contemporary Clinical Trials, 28, 32-41.
|
5 |
Chen TT (1997). Optimal three-stage designs for phase II cancer clinical trials, Statistics in Medicine, 16, 2701-2711.
DOI
|
6 |
Conaway MR and Petroni GR (1996). Designs for phase ii trials allowing for a trade-off between response and toxicity, Biometrics, 52, 1375-1386.
DOI
|
7 |
Ensign LG, Gehan EA, Kamen DS, and Thall PF (1994). An optimal three-stage design for phase II clinical trials, Statistics in Medicine, 13, 1727-1736.
DOI
|
8 |
Fleming TR (1982). One-sample multiple testing procedure for phase ii clinical trials, Biometrics, 38, 143-151.
DOI
|
9 |
Green SJ and Dahlberg S (1992). Planned versus attained design in phase II clinical trials, Statistics in Medicine, 11, 853-862.
DOI
|
10 |
Jung SH, Carey M, and Kim KM (2001). Graphical search for two-stage designs for phase II clinical trials, Controlled Clinical Trials, 22, 367-372.
DOI
|
11 |
Kim S and Wong WK (2017). Extended two-stage adaptive designs with three target responses for phase II clinical trials, Statistical Methods in Medical Research, 27, 3628-3642.
|
12 |
Mander AP and Thompson SG (2010). Two-stage designs optimal under the alternative hypothesis for phase II cancer clinical trials, Contemporary Clinical Trials, 31, 572-578.
DOI
|
13 |
Mander AP, Wason JM, Sweeting MJ, and Thompson SG (2012). Admissible two-stage designs for phase II cancer clinical trials that incorporate the expected sample size under the alternative hypothesis, Pharmaceutical Statistics, 11, 91-96.
DOI
|
14 |
Ray HE and Rai SN (2011). An evaluation of a Simon 2-stage phase II clinical trial design incorporating toxicity monitoring, Contemporary Clinical Trials, 32, 428-436.
DOI
|
15 |
Wason JM, Mander AP, and Eisen TG (2011). Reducing sample sizes in two-stage phase II cancer trials by using continuous tumour shrinkage end-points, European Journal of Cancer, 47, 983-989.
DOI
|
16 |
Rugo HS, Seneviratne L, Beck JT, et al. (2017). Prevention of everolimus-related stomatitis in women with hormone receptor-positive, her2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial, Lancet Oncol, 18, 654-662.
DOI
|
17 |
Simon R (1989). Optimal two-stage designs for phase II clinical trials, Controlled Clinical Trials, 10, 1-10.
DOI
|
18 |
Thall PF and Simon R (1994). Practical Bayesian guidelines for phase IIB clinical trials, Biometrics, 50, 337-349.
DOI
|
19 |
Zhou H, Lee JJ, and Yuan Y (2017). BOP2: Bayesian optimal design for phase II clinical trials with simple and complex endpoints, Statistics in Medicine, 36, 3302-3314.
DOI
|
20 |
Kwak M and Jung SH (2014). Phase II clinical trials with time-to-event endpoints: optimal two-stage designs with one-sample log-rank test, Statistics in Medicine, 33, 2004-2016.
DOI
|
21 |
Lee JJ and Liu DD (2008). A predictive probability design for phase II cancer clinical trials, Clinical Trials, 5, 93-106.
DOI
|